Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

4HPR triggers apoptosis but not differentiation in retinoid sensitive and resistant human embryonal carcinoma cells through an RARγ independent pathway

Oncogene volume 18, pages 5747–5755 (1999)Cite this article

Abstract

Retinoids signal biological effects through retinoic acid receptors (RAR) and retinoid X receptors (RXR) and their co-regulators. We previously reported that all-trans retinoic acid (RA) triggers terminal differentiation in the human embryonal carcinoma cell line NTERA-2 clone D1 (NT2/D1), through an RARγ dependent pathway. RARγ repression in NT2/D1-R1 cells accounts for RA resistance in this line. This report finds RARγ repression is due to selective repression of RARγ but not RARβ transcription in NT2/D1-R1 cells. The repression is neither due to mutations in RARγ nor its promoter containing the RA response element. Prior work was confirmed and extended by demonstrating that an RARγ selective agonist preferentially signals differentiation of NT2/D1 cells, while RARα/β, RARβ, RXR agonists and an RAR pan-antagonist do not even when NT2/D1 cells are treated with these retinoids at 10 μM dosages. None of these examined retinoids induced differentiation of the RA resistant NT2/D1-R1 cells. In contrast, N-(4-hydroxyphenyl)retinamide (4HPR), a reported transcriptional activator of RARγ was shown to potently induce growth inhibition and apoptosis in both NT2/D1 and NT2/D1-R1 cells. 4HPR-induced apoptosis was unaffected by co-treatment of both cell lines with equimolar RAR antagonist. Semi-quantitative reverse transcription-polymerase chain reaction (RT – PCR) assays of total RNA from 4HPR-treated NT2/D1 and NT2/D1-R1 cells did not reveal RARγ induction. Since 4HPR signals in RA-resistant NT2/D1-R1 cells having an RARγ transcriptional block, these results indicate that 4HPR triggers apoptosis but not differentiation through an RARγ independent pathway. Taken together, these findings implicate a therapeutic role for 4HPR mediated apoptosis in germ cell tumors even when a maturation block is present.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8

Similar content being viewed by others

References

  • Andrews PW. . 1984 Dev. Biol. 103: 285–293.

  • Bhatnagar DL, Abou-Issa H, Curley Jr RW, Koolemans-Beynen A, Moeschberger ML and Webb TE. . 1991 Biochem. Pharmacol. 41: 1471–1477.

  • Bosl GJ, Bajorin DB, Sheinfeld J and Motzer RJ. . 1997 In: Cancer: Principals and Practice of Oncology. Devita VT, Hellman S and Rosenberg SA (eds).. Philadelphia: JB Lippincott-Raven Company. pp.1397–1425.

    Google Scholar 

  • Boylan JF, Lohnes D, Taneja R, Chambon P and Gudas LJ. . 1993 Proc. Natl. Acad. Sci. USA 90: 9601–9605.

  • Boylan JF, Lufkin T, Achkar CC, Taneja R, Chambon P and Gudas LJ. . 1995 Mol. Cell. Biol. 15: 843–851.

  • Chen JY, Clifford J, Zusi C, Starrett J, Tortolani D, Ostrowski J, Reczek PR, Chambon P and Gronemeyer H. . 1996 Nature 382: 819–822.

  • Chomczynski P. . 1993 BioTechniques 15: 532–534.

  • Clifford JL, Petkovich M, Chambon P and Lotan R. . 1990 Mol. Endocrinol. 4: 1546–1555.

  • Clifford JL, Menter DG, Wang M, Lotan R and Lippman SM. . 1999 Cancer Res. 59: 14–18.

  • Delia D, Aiello A, Lombardi L, Pelicci PG, Grignani F, Grignani F, Formelli F, Menard S, Costa A, Veronesi U and Pierotti MA. . 1993 Cancer Res. 53: 6036–6041.

  • Delia D, Aiello A, Meroni L, Nicolini M, Reed JC and Pierotti MA. . 1997 Carcinogenesis 18: 943–948.

  • De Palo G, Camerini T, Marubini E, Costa A, Formelli F, Del Vecchio M, Mariani L, Miceli R, Mascotti G, Magni A, Campa T, Di Mauro MG, Attili A, Maltoni C, DelTurco MR, Decensi A, D'Aiuto G and Veronesi U. . 1997 Tumori. 83: 884–894.

  • Dmitrovsky E, Moy D, Miller Jr WH, Li A and Masui H. . 1990 Oncogene Res. 5: 233–239.

  • Dowlatshahi K, Mehta RG, Thomas CF, Dinger NM and Moon RC. . 1989 Cancer Lett. 47: 187–192.

  • Fanjul AN, Delia D, Pierotti MA, Rideout D, Qiu J and Pfahl M. . 1996 J. Biol. Chem. 271: 22441–22446.

  • Fontana JA, Reppucci A, Durham JP and Miranda D. . 1986 Cancer Res. 46: 2468–2473.

  • Formelli F, Barua AB and Olson JA. . 1996 FASEB 10: 1014–1024.

  • Giguere V, Ong ES, Segui P and Evans RM. . 1987 Nature 330: 624–629.

  • Grignani F, De Matteis S, Nervi C, Tomassoni L, Gelmetti V, Cioce M, Fanelli M, Ruthardt M, Ferrara FF, Zamir I, Seiser C, Grignani F, Lazar MA, Minucci S and Pelicci PG. . 1998 Nature 391: 815–818.

  • Gudas LJ, Sporn MB and Roberts AB. . 1994 In: The retinoids, biology, chemistry, and medicine. Sporn MB, Roberts AB and Goodman OS (eds).. Raven Press, New York. pp.443–520.

    Google Scholar 

  • Kastner P, Mark M, Ghyselinck N, Krezel W, Dupe V, Grondona JM and Chambon P. . 1997 Development 124: 313–326.

  • Kawasaki H, Eckner R, Yao TP, Taira K, Chiu R, Livingston DM and Yokoyama KK. . 1998 Nature 393: 284–288.

  • Kazmi SM, Plante RK, Visconti V and Lau CY. . 1996 Cancer Res. 56: 1056–1062.

  • Kurie JM, Buck J, Eppinger TM, Moy D and Dmitrovsky E. . 1993 Differentiation 54: 123–129.

  • Lehmann JM, Hoffmann B and Pfahl M. . 1991 Nucl. Acids Res. 19: 573–578.

  • Lehmann JM, Zhang XK and Pfahl M. . 1992 Mol. Cell. Biol. 12: 2976–2985.

  • Lin RJ, Nagy L, Inoue S, Shao W, Miller Jr WH and Evans RM. . 1998 Nature 391: 811–814.

  • Lotan R. . 1995 J. Natl. Cancer Inst. 87: 1655–1657.

  • Mangelsdorf DJ, Ong ES, Dyck JA and Evans RM. . 1990 Nature 345: 224–229.

  • Mangelsdorf DJ, Umesono K, Kliewer SA, Borgmeyer U, Ong ES and Evans RM. . 1991 Cell 66: 555–561.

  • Miller Jr WH, Maerz WJ, Kurie J, Moy D, Baselga J, Lucas D, Grippo JF, Masui H and Dmitrovsky E. . 1994 Differentiation 55: 145–152.

  • Moasser MM, Reuter VE and Dmitrovsky E. . 1995a Oncogene 10: 1537–1543.

  • Moasser MM, Motzer RJ, Khoo KS, Lyn P, Murphy BA, Bosl GJ and Dmitrovsky E. . 1995b Cancer 76: 680–686.

  • Moasser MM, Khoo KS, Maerz WJ, Zelenetz A and Dmitrovsky E. . 1996 Differentiation 60: 251–257.

  • Moasser MM, DeBlasio A and Dmitrovsky E. . 1994 Oncogene 9: 833–840.

  • Monzon RI, Fillmore C and Hudson LG. . 1997 Mol. Pharmacol. 51: 377–382.

  • Moon RC, Kelloff GJ, Detrisac CJ, Steele VE, Thomas CF and Sigman CC. . 1992 Anticancer Res. 12: 1147–1153.

  • Moon RC, Thompson HJ, Becci PJ, Grubbs CJ, Gander RJ, Newton DL, Smith JM, Phillips SL, Henderson WR, Mullen LT, Brown CC and Sporn M. . 1979 Cancer Res. 39: 1339–1346.

  • Nagpal S, Saunders M, Kastner P, Durand B, Nakshatri H and Chambon P. . 1992 Cell 70: 1007–1019.

  • Nason-Burchenal K, Allopenna J, Begue A, Stehelin D, Dmitrovsky E and Martin P. . 1998 Blood 92: 1758–1767.

  • Oridate N, Suzuki S, Higuchi M, Mitchell MF, Hong WK and Lotan R. . 1997 J. Natl. Cancer Inst. 89: 1191–1198.

  • Park DJ and Patek PQ. . 1997 BioTechniques 24: 558–559.

  • Petkovich M, Brand NJ, Krust A and Chambon P. . 1987 Nature 330: 444–450.

  • Pollard M and Luckert PH. . 1991 Cancer Lett. 59: 159–163.

  • Sheikh MS, Shao ZM, Li XS, Ordonez JV, Conley BA, Wu S, Dawson MI, Han QX, Chao WR, Quick T, Niles RM and Fontana JA. . 1995 Carcinogenesis 16: 2477–2486.

  • Spanjaard RA, Ikeda M, Lee PJ, Charpentier B, Chin WW and Eberlein TJ. . 1997 J. Biol. Chem. 272: 18990–18999.

  • Spinella MJ, Kitareewan S, Mellado B, Sekula D, Khoo KS and Dmitrovsky E. . 1998 Oncogene 16: 3471–3480.

  • Subbarayan V, Kastner P, Mark M, Dierich A, Gorry P and Chambon P. . 1997 Mech. Dev. 66: 131–142.

  • Taneja R, Bouillet P, Boylan JF, Gaub MP, Roy B, Gudas LJ and Chambon P. . 1995 Proc. Natl. Acad. Sci. USA 92: 7854–7858.

  • Taneja R, Rochette-Egly C, Plassat JL, Penna L, Gaub MP and Chambon P. . 1997 EMBO J. 16: 6452–6465.

Download references

Acknowledgements

We thank Dr Pierre Chambon (INSERM, France) for the use of RARγ1 cDNA, Dr Claudio Basilico (New York University Medical School) for the FGF4 reporter plasmid and Mr Zalman Suldan (Memorial Sloan-Kettering Cancer Center, NY, USA) for technical assistance. This work was supported by the American Cancer Society grant RPG-90-019-08-DDC (E Dmitrovsky). MJ Spinella was supported by a N.I.H. Howard Temin Award (K01 CA75154).

Author information

Authors and Affiliations

  1. Department of Pharmacology and Toxicology, 7650 Remsen, Dartmouth Medical School, Hanover, 03755, New Hampshire, NH, USA

    Sutisak Kitareewan, Michael J Spinella & Ethan Dmitrovsky

  2. Department of Medicine and Norris Cotton Cancer Center, Dartmouth Hitchcock Medical Center, Hanover, 03755, New Hampshire, NH, USA

    Ethan Dmitrovsky

  3. Memorial Sloan-Kettering Cancer Center, New York, 10021, NY, USA

    Janet Allopenna

  4. Bristol-Myers Squibb Pharmaceutical Research Institute, Buffalo, 14213-1091, New York, NY, USA

    Peter R Reczek

Authors
  1. Sutisak Kitareewan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael J Spinella
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Janet Allopenna
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Peter R Reczek
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ethan Dmitrovsky
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kitareewan, S., Spinella, M., Allopenna, J. et al. 4HPR triggers apoptosis but not differentiation in retinoid sensitive and resistant human embryonal carcinoma cells through an RARγ independent pathway. Oncogene 18, 5747–5755 (1999). https://doi.org/10.1038/sj.onc.1202981

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1202981

Keywords

This article is cited by

Search

Advanced search

Quick links